Lexston Life Sciences Corp. (LEXTF)
USD 0.02
(22.22%)
USD 0.02
(22.22%)
| Breakdown | 2024 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | 361.01 Thousand | 149.11 Thousand | - |
| Cost of Revenue | 26.39 Thousand | - | 151.5 Thousand | 100.27 Thousand | - |
| Gross Profit | -26.39 Thousand | - | 209.5 Thousand | 48.83 Thousand | - |
| Operating Expenses | 674.71 Thousand | 674.71 Thousand | 2.2 Million | 539.92 Thousand | 6483.00 |
| Selling, General and Administrative Expenses | 674.71 Thousand | 674.71 Thousand | 1.77 Million | 470.39 Thousand | 6483.00 |
| Research and Development Expenses | - | - | 125.44 Thousand | 43.19 Thousand | - |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 674.71 Thousand | 674.71 Thousand | 2.36 Million | 640.19 Thousand | 6483.00 |
| Operating Income | -674.71 Thousand | -674.71 Thousand | -1.58 Million | -433.42 Thousand | -6480.00 |
| Interest Expense | - | - | - | - | - |
| Income Tax Expense | - | 133.43 Thousand | 320.59 Thousand | 385.04 Thousand | -206.29 Thousand |
| Earnings before Tax | -734.28 Thousand | -734.28 Thousand | -2.32 Million | -876.13 Thousand | -6483.00 |
| Net Income | -867.71 Thousand | -867.71 Thousand | -2.32 Million | -876.13 Thousand | -6483.00 |
| Earnings Per Share Basic | -0.02 | -0.02 | -0.21 | -0.09 | -0.00 |
| Earnings Per Share Diluted | -0.03 | -0.03 | -0.21 | -0.09 | -0.00 |
| Weighted Average Shares Outstanding | 37.68 Million | 37.68 Million | 11.16 Million | 9.99 Million | 9.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 31.89 Million | 31.89 Million | 11.16 Million | 9.99 Million | 9.99 Million |
| Gross Margin | - | - | 0.58 | 0.33 | - |
| EBIT Margin | - | - | -4.56 | -0.64 | - |
| Profit Margin | - | - | -6.43 | -5.88 | - |
| EBITDA | -648.32 Thousand | -648.32 Thousand | -1.88 Million | -479.81 Thousand | -6480.00 |
| Earnings Before Tax Margin | - | - | -4.38 | -2.91 | - |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | 6574.00 | 6574.00 | 6623.00 | 29.8 Thousand | 6966.00 |
| Gross Profit | - | -6574.00 | -6574.00 | -6623.00 | -29.8 Thousand | -6966.00 |
| Operating Expenses | 132.81 Thousand | 366.1 Thousand | 131.6 Thousand | 105.79 Thousand | 1.04 Million | 63.15 Thousand |
| Selling, General and Administrative Expenses | 85.37 Thousand | 366.1 Thousand | 99.35 Thousand | 72.61 Thousand | - | -43.55 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 47.44 Thousand | - | - | - | - | - |
| Cost and Expenses | 113.04 Thousand | 372.67 Thousand | 138.17 Thousand | 112.41 Thousand | 1.07 Million | 70.12 Thousand |
| Operating Income | -113.04 Thousand | -372.68 Thousand | -101.83 Thousand | -83.16 Thousand | -790.76 Thousand | -51.63 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 133.43 Thousand | -4.00 | -36.33 Thousand | -29.25 Thousand | 34.92 Thousand | 13.99 Thousand |
| Earnings before Tax | -113.04 Thousand | -372.67 Thousand | -138.17 Thousand | -112.41 Thousand | -1.1 Million | -84.12 Thousand |
| Net Income | -246.47 Thousand | -372.67 Thousand | -138.17 Thousand | -112.41 Thousand | -1.1 Million | -84.12 Thousand |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.00 | -0.00 | - | -0.00 |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.00 | -0.00 | - | -0.00 |
| Weighted Average Shares Outstanding | 32 Million | 32 Million | 30.31 Million | 30.3 Million | 28.58 Million | 30.3 Million |
| Weighted Average Shares Outstanding (Diluted) | 32 Million | 32 Million | 30.31 Million | 30.3 Million | 28.58 Million | 30.3 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -106.42 Thousand | -366.11 Thousand | -131.6 Thousand | -105.79 Thousand | - | -49.15 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
SUNILTX
GPMT
CRBO
PIAIF
EKC
NMGC